Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-22T08:11:38.508Z Has data issue: false hasContentIssue false
  • English
  • Français

Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial

Published online by Cambridge University Press:  02 January 2018

Nikolaj Kun⊘e ,
Philipp Lobmaier ,
John Kåre Vederhus ,
Bj⊘rg Hjerkinn ,
Solfrid Hegstad ,
Michael Gossop ,
Øistein Kristensen  and
Helge Waal
Nikolaj Kun⊘e*
Affiliation:
Norwegian Centre for Addiction Research, Oslo
Philipp Lobmaier
Affiliation:
Norwegian Centre for Addiction Research, Oslo
John Kåre Vederhus
Affiliation:
Addiction Unit, S⊘rlandet Hospital, Kristiansand
Bj⊘rg Hjerkinn
Affiliation:
Addiction Unit, S⊘rlandet Hospital, Kristiansand
Solfrid Hegstad
Affiliation:
Norwegian Institute of Public Health, Division of Forensic Toxicology and Drug Abuse, Oslo, Norway
Michael Gossop
Affiliation:
National Addiction Centre, Maudsley Hospital, and Institute of Psychiatry, King's College London, UK
Øistein Kristensen
Affiliation:
Addiction Unit, S⊘rlandet Hospital, Kristiansand
Helge Waal
Affiliation:
Norwegian Centre for Addiction Research, Oslo, Norway
*
Nikolaj Kun⊘e, Norwegian Centre for Addiction Research, Kirkeveien 166, NO-0407 Oslo, Norway. Email: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

Naltrexone has considerable potential in helping to prevent relapse in heroin dependency. A longer-lasting formulation for naltrexone treatment is desirable to further reduce non-adherence and relapse during treatment of opiate dependence.

Aims

To evaluate the safety and effectiveness of a 6-month naltrexone implant in reducing opioid use after in-patient treatment.

Method

A group of 56 abstinence-oriented patients who completed in-patient treatment for opioid dependence were randomly and openly assigned to receive either a 6-month naltrexone implant or their usual aftercare. Drug use and other outcomes were assessed at 6-month follow-up.

Results

Patients receiving naltrexone had on average 45 days less heroin use and 60 days less opioid use than controls in the 180-day period (both P<0.05). Blood tests showed naltrexone levels above 1 ng/ml for the duration of 6 months. Two patients died, neither of whom had received an implant.

Conclusions

Naltrexone implant treatment safely and significantly reduces opioid use in a motivated population of patients.

Type
Papers
Information
The British Journal of Psychiatry , Volume 194 , Issue 6 , June 2009 , pp. 541 - 546
Copyright
Copyright © Royal College of Psychiatrists, 2009 

Footnotes

Declaration of interest

None.

References

1 Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Arch Gen Psychiatry 1978; 35: 335–40.Google Scholar
2 Minozzi, S, Amato, L, Vecchi, S, Davoli, M, Kirchmayer, U, Verster, A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2006; 1: CD001333.Google Scholar
3 Sullivan, MA, Rothenberg, JL, Vosburg, SK, Church, SH, Feldman, SJ, Epstein, EM, et al. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am J Addict 2006; 15: 150–9.CrossRefGoogle ScholarPubMed
4 Greenstein, RA, Arndt, IC, McLellan, AT, O'Brien, CP, Evans, B. Naltrexone: a clinical perspective. J Clin Psychiatry 1984; 45: 25–8.Google ScholarPubMed
5 Bell, JR, Young, MR, Masterman, SC, Morris, A, Mattick, RP, Bammer, G. A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med J Aust 1999; 171: 26–30.CrossRefGoogle ScholarPubMed
6 Hulse, GK, Basso, MR. The association between naltrexone compliance and daily supervision. Drug Alcohol Rev 2000; 19: 41–8.CrossRefGoogle Scholar
7 Waal, H, Aamodt, O, Olsen, H. [Use of naltrexone in the treatment of young drug addicts.] Tidsskr Nor Laegeforen 2003; 123: 1662–4.Google ScholarPubMed
8 Comer, SD, Sullivan, MA, Hulse, GK. Sustained-release naltrexone: novel treatment for opioid dependence. Expert Opin Investig Drugs 2007; 16: 1285–94.CrossRefGoogle ScholarPubMed
9 Comer, SD, Sullivan, MA, Yu, E, Rothenberg, JL, Kleber, HD, Kampman, K, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 210–8.CrossRefGoogle ScholarPubMed
10 Lobmaier, P, Kornor, H, Kunoe, N, Bjorndal, A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008; 2: CD006140.Google Scholar
11 Brewer, C. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases. Addict Biol 2002; 7: 321–3.CrossRefGoogle ScholarPubMed
12 Foster, J, Brewer, C, Steele, T. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol 2003; 8: 211–7.CrossRefGoogle ScholarPubMed
13 Carreno, JE, Alvarez, CE, San Narciso, GL, Bascarán, MT, Díaz, M, Bobes, J, et al. Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. Addict Biol 2003; 8: 429–38.CrossRefGoogle ScholarPubMed
14 Hulse, GK, Arnold-Reed, DE, O'Neil, G, Chan, CT, Hansson, R, O'Neil, P. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol 2004; 9: 59–65.CrossRefGoogle ScholarPubMed
15 Hulse, GK, Tait, RJ, Comer, SD, Sullivan, MA, Jacobs, IG, Arnold-Reed, D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend 2005; 79: 351–7.CrossRefGoogle ScholarPubMed
16 Ngo, HT, Arnold-Reed, DE, Hansson, RC, Tait, RJ, Hulse, GK. Blood naltrexone levels over time following naltrexone implant. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 23–8.CrossRefGoogle ScholarPubMed
17 Reece, AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy 2007; 2: 35.CrossRefGoogle Scholar
18 Waal, H, Christophersen, AS, Frogopsahl, G, Olsen, LH, Morland, J. [Naltrexone implants – a pilot project.] Tidsskr Nor Laegeforen 2003; 123: 1660–1.Google ScholarPubMed
19 Olsen, L, Christophersen, AS, Frogopsahl, G, Waal, H, Morland, J. Plasma concentrations during naltrexone implant treatment of opiate-dependent patients. Br J Clin Pharmacol 2004; 58: 219–22.CrossRefGoogle ScholarPubMed
20 Waal, H, Frogopsahl, G, Olsen, L, Christophersen, AS, Morland, J. Naltrexone implants – duration, tolerability and clinical usefulness. A pilot study. Eur Addict Res 2006; 12: 138–44.CrossRefGoogle ScholarPubMed
21 Waal, H. Merits and problems in high-threshold methadone maintenance treatment. Evaluation of medication-assisted rehabilitation in Norway 1998–2004. Eur Addict Res 2007; 13: 66–73.CrossRefGoogle ScholarPubMed
22 McLellan, AT, Kushner, H, Metzger, D, Peters, R, Smith, I, Grissom, G, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9: 199–213.CrossRefGoogle ScholarPubMed
23 Sobell, LC, Sobell, MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In Measuring Alcohol Consumption: Psychosocial and Biochemical Methods (eds Litten, RZ & Allen, JP): 41–72. Humana Press, 1992.CrossRefGoogle Scholar
24 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). APA, 1994.Google Scholar
25 Sheehan, DV, Lecrubier, Y. Mini-International Neuropsychiatric Interview (English version 5.00). University of South Florida, 1998.Google ScholarPubMed
26 Kotkevi, A, Hargers, C. EUROPASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res 1995: 1: 208–10.Google Scholar
27 Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71.CrossRefGoogle ScholarPubMed
28 Derogatis, LR, Lipman, RS, Rickels, K, Uhlenhuth, EH, Covi, L. et al. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci 1974; 19: 1–15.CrossRefGoogle ScholarPubMed
29 Pavot, W, Diener, E, Suh, E. The Temporal Satisfaction With Life Scale. J Pers Assess 1998; 70: 340–54.CrossRefGoogle Scholar
30 Hegstad, S, Khiabani, H, Kristoffersen, L, Kunøe, N, Lobmaier, P, Christophersen, AS. Drug screening of hair by liquid chromatography–tandem mass spectrometry. J Anal Toxicol 2008; 32: 364–72.CrossRefGoogle Scholar
31 Shearer, J, White, B, Gilmour, S, Wodak, AD, Dolan, KA. Hair analysis underestimates heroin use in prisoners. Drug Alcohol Rev 2006; 25: 425–31.CrossRefGoogle ScholarPubMed
32 Gossop, M, Stewart, D, Browne, N, Marsden, J. Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effect of coping responses. Addiction 2002; 97: 1259–67.CrossRefGoogle ScholarPubMed
33 Garbutt, JC, Kranzler, HR, O'Malley, SS, Gastfriend, DR, Pettinati, HM, Silverman, BL, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293: 1617–25.CrossRefGoogle ScholarPubMed
34 Pettinati, HM, O'Brien, CP, Rabinowitz, AR, Wortman, SP, Oslin, DW, Kampman, KM, et al. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol 2006; 26: 610–25.CrossRefGoogle ScholarPubMed
35 O'Malley, SS, Garbutt, JC, Gastfriend, DR, Dong, Q, Kranzler, HR. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol 2007; 27: 507–12.CrossRefGoogle ScholarPubMed
Supplementary material: PDF

Kun⊘e et al. supplementary material

Supplementary Table S1

Download Kun⊘e et al. supplementary material(PDF)
PDF 39.9 KB
Submit a response

eLetters

No eLetters have been published for this article.